AET2023: Fully Human Anti-TIGIT Blocking Monoclonal Antibodies Demonstrate Potent Anti-Tumor Efficacy
Summary We obtained novel, differentiating, fully human anti-TIGIT clones with the following properties and activities • High binding affinity • Distinct epitopes from several clinical…
Read moreAET2023: Discovery of a fully human TCR-mimic antibody developed to target NY-ESO-1/HLA-A02
Summary Biocytogen’s TCRm antibody discovery platform combines unique immune technology with a multiplex screening method to obtain a high-affinity NY-ESO-1/HLA-A02 antibody, which can bind and…
Read moreAET2023: Discovery of RenNano®-derived human heavy-chain-only TFR1 antibodies that can efficiently cross the blood-brain barrier and deliver drug payload
Summary • hTFR1-targeting HCAbs developed from RenNano® mice have nM range affinity to human TFR1, and have functional capabilities, including internalization capacity. • hTFR1-targeting HCAbs…
Read moreESMO2023: Phase I open-label, dose escalation and expansion study of YH003 in combination with Toripalimab in patients with advanced solid tumors
Conclusions YH003 was well tolerated up to 1.0 mg/kg dose levels when combined with Toripalimab. Based on the safety, efficacy and PK data of YH003002,…
Read morePreclinical Application of a Fully Human TCR-mimic Antibody Developed to Target NY-ESO-1/HLA-A02
SUMMARY Biocytogen’s TCRm antibody discovery platform combines unique immune technology with a multiplex screening method to obtain a high-affinity NY-ESO-1/HLA-A02 antibody, which can bind and…
Read moreIdentification of fully human TCR-mimic antibodies targeting the KRAS G12V/HLA complex generated in HLA-transgenic RenMab mice
SUMMARY We identified TCR-mimic antibodies specific for KRAS G12V residues 7-16 complexed with HLA-A03 or HLA-A11. Both anti-KRAS G12V/HLA-A11 and anti-KRAS G12V/HLA-A03 antibodies showed abundant…
Read moreFc-Competent Fully Human Anti-TIGIT Blocking Monoclonal Antibodies Demonstrated Potent Anti-Tumor Efficacy in Preclinical Models
SUMMARY We obtained novel, differentiating, fully human anti-TIGIT clones with the following properties and activities: • High binding affinity • Distinct epitopes from several clinical…
Read moreSITC 2023: BSA01, a Bispecific Antibody-drug Conjugate Targeting EGFR and Membrane-bound MUC1-C, Exhibits Anti-tumor Efficacy In Vivo Efficacy Against Triple-negative Breast Cancer Xenografts
SUMMARY Co-expression of EGFR and MUC1 in multiple solid tumors suggests that simultaneous targeting of EGFR and MUC1 with bsADC has the potential to enhance…
Read moreSITC 2023: A Novel Bispecific Antibody-drug Conjugate Targeting PTK7 and TROP2, BCG033, Demonstrates Preclinical Efficacy Against Triple-negative Breast Cancer Xenografts
SUMMARY PTK7 and TROP2 are two tumor-associated antigens (TAAs) highly expressed in TNBC and other solid tumors. The PTK7 x TROP2 bsAbs showed enhanced internalization…
Read moreSITC 2023: BCG022: A HER3×MET Bispecific Antibody-drug Conjugate (BsADC) Targeting Key Mechanisms of Bypass Resistance in Multiple Tumor Types
SUMMARY HER3 and MET were co-expressed in various tumor types, and their signaling plays a key role in EGFR TKI drug resistance. HER3×MET bsAbs generated…
Read morePreclinical CD3-based Mouse Models for Evaluation of Bi-specific T-cell Engager Antibodies
SUMMARY mRNA and protein expression analysis: Human Cd3e mRNA was exclusively detected B-hCD3E mice and human Cd3e, Cd3d, Cd3g mRNAs were exclusively detected in B-hCD3EDG…
Read moreHumanized ICOS Mice as a Novel Tool for Predicting and Monitoring T-cell-mediated Immunotherapy Response
SUMMARY mRNA expression analysis: Mouse Icos mRNA was detected in thymic tissue isolated from wild-type and heterozygous B-hICOS (H/+) mice. Human ICOS mRNA was detected…
Read more